Robert Petrika*
The Glucagon-Like Peptide-1 Receptor (GLP1R) is a receptor protein present on pancreatic beta cells as well as brain neurons. It helps to regulate blood sugar levels by increasing insulin secretion. The GLP-1RAs have been found to lower body weight and improve glycemic indices. These drugs function by activating GLP-1 receptors in the pancreas, resulting in increased insulin release and decreased glucagon release-both glucose-dependent responses-and a reduced risk of hypoglycemia. Diabetes is caused by a lack of insulin and an oversupply of glucagon. Extra pancreatic glucagon was identified in dogs, which overturned the prevalent orthodoxy and allowed for detailed examination of the functions of insulin and glucagon in physiology and diabetes, as well as definitive proof about the involvement of glucagon in diabetes. Glucagon was thought to have impacts on many organs prior to his studies, but he was the first to assess the physiological role of glucagon using the effect of glucagon on glucose turnover. He was the first to say that glucagon only affects the liver, contrary to popular perception. He was also the first to quantify insulin secretion physiologically.
Published Date: 2022-03-29; Received Date: 2022-02-23
